The Role of MyD88 in Breast Cancer Prognosis
Author Information
Author(s): Yu Xin, Zhang Qinfang, Li Bei, Sun Shengrong, Li Juanjuan, Li Wenge
Primary Institution: Renmin Hospital of Wuhan University
Hypothesis
This study aims to explore the prognostic significance and immunological implications of MyD88 in breast cancer.
Conclusion
Elevated MyD88 expression is associated with improved patient outcomes and may serve as a predictive biomarker for therapeutic response in breast cancer.
Supporting Evidence
- High MyD88 expression is linked to better patient prognoses.
- MyD88 high-expressing tumors are more sensitive to chemotherapy.
- A nomogram incorporating MyD88 improves survival probability estimates.
- Patients with high MyD88 expression have a favorable immune landscape.
- Elevated MyD88 expression correlates with increased immune cell infiltration.
Takeaway
MyD88 is a protein that helps doctors understand how breast cancer behaves, and higher levels of it can mean better outcomes for patients.
Methodology
The study used bulk RNA sequencing, single-cell RNA sequencing, and immunohistochemistry to analyze MyD88 expression in breast cancer patients.
Potential Biases
Potential confounding factors in determining causality due to the retrospective nature of the study.
Limitations
The study is retrospective and based on a single clinical center, which may introduce bias.
Participant Demographics
The study involved 1091 patients from the TCGA-BRCA cohort and 100 female patients from the IHC cohort.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website